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ABSTRACT: A sequential docking methodology was applied to computationally predict starting points for fragment link-
ing using the human dopamine D3 receptor crystal structure and a human dopamine D2 receptor homology model. Two 
focused fragment libraries were docked in the primary and secondary binding sites and best fragment combinations were 
enumerated. Similar top scoring fragments were found for the primary site, while secondary site fragments were predicted 
to convey selectivity. Three linked compounds were synthesized that had 9, 39 and 55-fold selectivity in favor of D3 and 
the subtype selectivity of the compounds was assessed on a structural basis. 
Fragment-based drug discovery (FBDD) has recently 
proved to have significant utility in early phase drug re-
search.1 Fragments are polar compounds of low molecular 
weight and low complexity enabling more efficient sam-
pling of chemical space and exploring enthalpy dominat-
ed targeting of protein hot spots resulting in better physi-
co-chemical and ADMET profiles of fragment derived 
leads and clinical candidates.2 The two main strategies of 
fragment hit elaboration are growing and linking.3 In the 
first one a single fragment is decorated with additional 
functionalities while in the second two (or more) frag-
ments are identified that bind to the target simultaneous-
ly and in close proximity and are subsequently incorpo-
rated in a single molecule using a suitable linker moiety. 
Although FBDD in the last decade has shown remarka-
ble efficiency on enzyme targets, its applicability for 
membrane proteins has been limited by difficulties in 
obtaining structural information on membrane proteins 
and application of sensitive biophysical screening meth-
ods frequently used for fragment screening such as high-
throughput X-ray screening, surface plasmon resonance 
(SPR) and nuclear magnetic resonance (NMR). Recent 
advances in G protein-coupled receptor stabilization and 
structural investigation made it possible to develop bio-
physical assays for GPCRs and to utilize structural infor-
mation in structure-based drug design. Several recent 
reports described experimental4 and virtual fragment 
screening5,6 as well as structure-guided optimization ef-
forts7 on GPCRs. It is expected that FBDD applied to 
GPCRs can provide novel and high quality compounds for 
this target family. 
Recent clinical evidence supports the effectiveness of 
dual dopamine D2 and D3 antagonists or partial agonists 
in schizophrenia, depression and bipolar mania.8 D D2 
antagonism is required for the antipsychotic effect and D3 
antagonism contributes to cognitive enhancement and 
reduced catalepsy. Finding the balance between D3 and D2 
affinities is essential for a beneficial therapeutic effect and 
safety profile. Dual acting compounds should show higher 
affinity to the D3 than to the D2 receptors due to different 
expression levels of the two receptors in specific brain 
areas. Since the elucidation of the dopamine D3 crystal 
structure in complex with eticlopride in 2010,9 much at-
tention has been directed towards the structure-based 
screening and design of D3 ligands. We have recently 
evaluated the performance of a sequential docking meth-
odology to computationally predict starting points for 
fragment linking.10 In the present study we apply this 
methodology for fragment docking and linking to the D3 
crystal structure and a D2 homology model and assess the 
subtype selectivity of the compounds on a structural ba-
sis. A similar methodology was also used by Abagyan et 
al. with dopamine as the fixed primary site ligand and no 
subsequent linking of the identified fragments.11 
Homology modeling and protein structure prepa-
ration. The human dopamine D2 receptor amino acid 
sequence from the UniProt server12 was aligned to the 
sequence of the template, chain A of the 2.89 Å resolution 
X-ray structure of the human dopamine D3 receptor crys-
tallized with the D2-D3 dual antagonist eticlopride (PDB 
code: 3PBL) using Prime 3.213 (see alignment in Support-
ing Information). The third intracellular loop was not 
modeled and the eticlopride ligand was included in ho-
mology model building to prevent collapse of the binding 
site. Finally the whole structure was subjected to Impref 
restrained minimization in the Protein Preparation Wiz-
ard in the Schrödinger Suite 2013.14 Chain A of the dopa-
mine D3 crystal structure was subjected to the full Protein 
Preparation Wizard workflow with default settings. 
Ligand preparation and docking. An in-house fo-
cused library of 196 fragments was collected containing a 
basic amine moiety in an aliphatic ring connected directly 
or through a short linker to a substituted aryl or hetaryl 
moiety (see general formula in the Supporting Infor-
 mation). Such compounds were believed to function as 
primary binding site ligands of the D2 and D3 receptors. It 
has been shown that the primary binding sites of the two 
receptors are nearly identical and selectivity can be 
achieved by modulation in the secondary binding pock-
et.15 Another in-house focused library of 266 fragments 
were collected containing a cyclohexyl or piperidine ring 
(see general formula in the Supporting Information) as 
these fragments were believed to function as secondary 
binding site ligands based on known D3 antagonists such 
as SB-27701116 suitable for modulating selectivity. The two 
libraries were prepared for docking using LigPrep 2.6.17 
Protonation and tautomeric states at pH 7±2 were enu-
merated using Epik 2.4.18 The Glide 5.919 software was 
used for sequential docking the two libraries to the two 
receptor structures according to the protocol described in 
ref. 10, briefly: the first library was docked to the apo re-
ceptor structures, then the docking poses were merged 
with the receptor, new grids were constructed including 
the merged ligands and the second fragment library was 
docked to the partially occupied binding sites (see Sup-
porting Information for additional computational details). 
Top scoring fragment combinations were visually inspect-
ed; linked compounds were synthesized and tested in 
radioligand binding assays. 
Primary site docking results. Docking of the first fo-
cused library of basic fragments produced results similar 
binding modes as in ref. 15. All of the 196 fragments could 
be docked into the inner binding site of the D3 receptor, 
of which 145 produced an ionic hydrogen bond to the 
characteristic Asp1103.32 in the D3 crystal structure and the 
aromatic moiety encased between hydrophobic residues 
Phe3456.51, Phe3466.52, Val1113.33 and Ile18345.52. The top 15 
fragments in D3 docking also achieved high ranks when 
the same library was docked to the D2 crystal structure, 
particularly the highest scoring 1-(3-cyano-5-
trifluoromethylphenyl)piperazine was identical in both 
receptors providing good docking scores (-8.576 for D3 
and -8.745 for D2) and identical binding modes. This is in 
line with the highly conserved nature of the primary bind-
ing site. Docking seemed to favor a meta-trifluoromethyl 
substituent in further high ranking fragments as well. 
Binding modes of the four top ranked compounds are 
depicted in Figure 1. 
Secondary site docking results. The 145 well-docked 
fragments were merged with the apo D3 structure allow-
ing for 145 new grids to be constructed and the second 
focused fragment library was docked to all of these new 
grids of partially occupied binding site. Docking scores of 
Figure 1. Binding modes of the top four fragments (from A to 
D) in D3 primary site docking. In A) the D3 and D2 binding 
sites are overlaid in grey and light blue carbons respectively, 
as well as docked poses of the ligand in orange and green 
carbons respectively. From B) to D) only D3 results are 
shown. Helix 6 is omitted for clarity. Compound structures 
are shown as insets. 
the 266 fragments in all 145 D3 grids were averaged and 
ranked by this mean docking score. Since docking might 
be sensitive to small differences of the grid used this pro-
cedure was used identifying secondary site fragments that 
bind next to different primary site fragments and fur-
thermore for the more robust estimation of the 
GlideScore. The single best primary site ligand was also 
merged with the apo D2 homology model and the second 
library was docked into this partially occupied structure 
to assess structural determinants of selectivity. Top rank-
ing secondary site binders in the D3 receptor and their 
binding modes in the D2 receptor were visually inspected. 
The binding modes of the top three fragments by mean 
D3 docking score in ten D3 grids and the single D2 grid are 
shown in Figure 2. It can be seen that these fragments 
produce extensive H-bonding patterns in the secondary 
binding site of the D3 crystal structure. Carbonyl groups 
of the cyclohexylurea (mean docking score: -6.574) and 
the cyclohexylglycinamide (mean docking score: -6.230) 
and one of the S=O groups of the cyclohexylaminosulfon-
amide (mean docking score: -6.087) act as acceptors for 
Thr3697.39 in D3 and the homologous Thr412
7.39 in D2. Two 
NH groups of all three ligands interact as donors to 
Glu902.65 and Ser3667.36 in D3 as well as the same Glu95
2.65 
and Ser4097.36 amino acids in D2. The only interaction 
different between the two receptor subtypes is the second 
S=O group of the cyclohexylaminosulfonamide fragment, 
which acts as an acceptor for Tyr361.39 in D3, while in the 
homologous position of D2 Leu41
1.39 can be found incapa-
ble of forming a hydrogen bond with the ligand. 
 Figure 2. Binding modes of the top three fragments in D3 and D2 secondary site docking. The D3 and D2 binding sites are over-
laid in grey and light blue carbons respectively, as well as an ensemble of 10 docked poses of the ligand in D3 in orange carbons 
and a single docked pose of the ligand in D2 in green carbons. Only the top ranked primary site ligand is included for clarity. 
Compound structures are shown as insets. 
Table 1. Experimental and docking data of linked compounds. 
Entry Compound structure hD3R Ki 
(nM)
a 
hD3R docking 
score 
hD2R Ki 
(nM)
a 
hD2R docking 
score 
Selectivity 
1 
N
N
F
F
F
N
N N
O
H
H
H
 
0.75 ± 0.10 -10.393 30 ± 11 -10.664 39 
2 
N
N
F
F
F
N
N
O
H
N
H
H
 
0.62 ± 0.23 -10.488 5.4 ± 0.2 -11.210 9 
3 
N
N
F
F
F
N
N
S
N
H
H
H
O O
 
0.67 ± 0.15 -10.514 37 ± 9 -10.833 55 
a
Inhibition constants from binding experiments on recombinant human D2 and D3 receptors. For details on the assays, see the 
Supporting Information. The data are derived from at least three independent experiments; the standard error of the mean is 
indicated. 
Furthermore, these ligands were found to produce ro-
bust binding modes in most of the 145 D3 grids. In fact, we 
identified 115, 109 and 94 out of 145 binding poses for urea, 
glycinamide and sulfonamide fragments, respectively in 
the different grids within 1.5 Å RMSD of the pose docked 
to the grid with the best primary site ligand included. As 
can be seen from Figure 2 the predicted binding modes of 
the second-site ligands in the grids containing the top ten 
primary site ligands are almost identical in the case of the 
urea and the sulfonamide fragment and show little varia-
bility for the glycinamide derivative. Robust ensembles of 
docking poses have been associated with higher reliability 
of the predicted binding mode20 and a higher entropy 
change upon binding.21 It is our experience and also 
shown in the literature that docking in some cases can be 
sensitive to grid centering, grid spacing, small differences 
in input geometries and even atom numbering.22 There-
fore a binding mode of a fragment that is seen in many 
similar grids of the protein is considered being more reli-
able than a binding mode that is only produced with 
specific grids. In the present case it also suggests that 
such secondary site fragments might bind proximally to 
different primary site fragments. Other fragments pro-
duced less robust binding modes. Therefore these top 
 three fragments predicted to bind the secondary site were 
selected for linking with the top primary aryl-piperazine 
fragment. Docking suggested possible linking of the basic 
aryl-piperazine nitrogen with either the para or the meta 
position of the cyclohexyl rings of the secondary frag-
ments. The distance of the para positions in the various 
docking poses ranged from 3.8 to 4.5 Å while the distance 
of the meta positions ranged from 3.4 to 3.6 Å, thus both 
seemed to be suitable linking points. Because of synthetic 
accessibility and fewer possible stereoisomers, linking was 
carried out at the symmetric para position. 
Biological activities. Linked compounds 1-3 were syn-
thesized and tested in in vitro [3H]raclopride binding 
experiments against recombinant human D2 and D3 re-
ceptors. See Supporting Information for synthetic routes 
and experimental details. The ligand displacement exper-
iments were repeated at least three times. Ki values and 
derived selectivities of the compounds are shown in Table 
1. The linked compounds possessed subnanomolar activi-
ties against the D3 receptor and low- to mid-nanomolar 
activity against the D2 receptor. The selectivity of com-
pound 2 was lowest, only 9 times higher Ki was measured 
for D2 than for D3, which is in line with the higher flexibil-
ity and less robust predicted binding mode of the second-
ary site fragment. On the other hand, compound 3 
showed a 55 times higher Ki for D2 than to D3, which is 
also supported by the docking results. This was the only 
compound featuring an extra D3 specific interaction, 
namely the H-bond with Tyr361.39, which is not present in 
D2. Docking of the linked compounds to the apo struc-
tures provided similar binding modes and the same H-
bonding pattern as the original unlinked fragments (data 
not shown). Only a small upward shift of the aryl-
piperazine fragment was evident in the primary binding 
site (RMSD: 1.7 Å) and very small deviations were seen in 
the secondary fragment binding modes (RMSD: 0.57 Å for 
the urea, 1.06 Å for the glycinamide and 0.84 Å for the 
sulfonamide fragment). The docking scores of the linked 
compounds were very high, and in this particular case the 
relative values of compounds at both receptors were in 
accordance with the experimental data (see Table 1). 
However, their selectivity could not be predicted, proba-
bly due to the different grids used. Relative scales of dock-
ing scores might be slightly different even for two grids of 
the same receptor. The prediction of selectivity using 
docking scores only is usually more reliable if selectivity 
ratios are larger. Finally, we note that the linked com-
pounds have favorable physico-chemical properties. The 
water-octanol partition coefficient (clogP) calculated by 
ChemAxon cxcalc23 of 2 and 3 is 2.5 and 3.1 for compound 
1 lying in the optimal range for orally active drugs. Ac-
cordingly, they exhibit favorable ligand lipophilicity effi-
ciency values (LLE = pKi-clogP > 5 is favorable) and lig-
and-efficiency-dependent lipophilicity values (LELP = 
0.73·clogP·HAC/pKi < 10 is favorable). LLE is 6.0 for 1 and 
6.7 for 2 and 3. LELP is 7.6 for 1 and 6.2 for 2 and 3 antici-
pating a favorable safety profile.24 
In conclusion we have applied our sequential fragment 
docking methodology to identify fragments to link in a 
GPCR target, namely the dopamine D3 receptor binding 
site. A homology model was also built for the D2 receptor 
subtype and docking of the fragments as well as the full 
linked compounds was carried out to both receptors in 
order to assess the structural basis of subtype selectivity 
of the predicted binders. Three linked compounds were 
synthesized and docking predictions were validated by 
the experimental results. Thus it has been shown that 
multiple fragment docking can provide starting points for 
linking for GPCR targets with elucidated 3D structures, 
and subtype selectivity has been achieved by virtual sec-
ondary site fragment screening and fragment linking. 
Supporting Information. General formulae of the focused 
fragment libraries, synthetic and experimental details. This 
material is available free of charge via the Internet at 
http://pubs.acs.org. 
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